Predictive value of interleukin-5 and monocyte chemotactic protein-1 for bacteremia in children with febrile neutropenia

Journal of Pediatric Hematology/oncology
V M AquinoPatrick Leavey

Abstract

A variety of clinical and laboratory parameters have been used to predict bacteremia. We hypothesize that the generation of a cytokine profile could be used to identify patients at higher risk of bacteremia at the time of presentation with febrile neutropenia. We prospectively evaluated children with cancer who presented with an episode of febrile neutropenia. A multiplexed flow cytometric assay was performed which measured 15 cytokines and chemokines obtained before the initiation of antibiotics. Fifty-eight episodes of chemotherapy-induced febrile neutropenia were included in this study during which 4 patients (7%) had bacteremia. An interleukin-5 level of >8 pg/dL had a sensitivity of 67% and a specificity of 96% to predict bacteremia. An monocyte chemotactic protein-1 level >1650 pg/dL had a sensitivity of 80% and a specificity of 82% to predict bacteremia. Erythrocyte sedimentation rate, C-reactive protein, protein C, and other cytokines/chemokines were not predictive of bacteremia. Elevations of interleukin-5 and monocyte chemotactic protein-1 are predictive of bacteremia in children with cancer who have febrile neutropenia. Prospective studies should be undertaken to determine whether these parameters retain predictive v...Continue Reading

References

Jul 27, 1992·FEBS Letters·M Baggiolini, I Clark-Lewis
Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A TalcottL Goldman
Dec 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C A Mullen, G R Buchanan
Jan 1, 1994·British Journal of Haematology·A WaageJ Lamvik
May 6, 1993·The New England Journal of Medicine·P A Pizzo
Dec 1, 1995·British Journal of Haematology·P EngervallM Björkholm
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W R RackoffP B Breitfeld
Aug 24, 1999·Scandinavian Journal of Rehabilitation Medicine·A NieuwboerB Baunach
Oct 31, 2000·Scandinavian Journal of Infectious Diseases·C ArberA Gratwohl
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M E SantolayaM Zubieta
Aug 8, 2002·Journal of Immunological Methods·Jonathan Seideman, David Peritt
Jan 11, 2003·Clinical and Diagnostic Laboratory Immunology·Wilco de JagerGer T Rijkers
Feb 26, 2005·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Glenn R StryjewskiHeidi Dalton
May 31, 2008·Current Opinion in Immunology·Kiyoshi Takatsu, Hiroshi Nakajima
May 16, 2009·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Satish L DeshmaneBassel E Sawaya

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.